References
- Adcock, S. A., & McCammon, J. A. (2006). Molecular dynamics: Survey of methods for simulating the activity of proteins. Chemical Reviews, 106(5), 1589–1615. https://doi.org/https://doi.org/10.1021/cr040426m
- Alberti, C., Pinciroli, P., Valeri, B., Ferri, R., Ditto, A., Umezawa, K., Sensi, M., Canevari, S., & Tomassetti, A. (2012). Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene, 31(37), 4139–4149. https://doi.org/https://doi.org/10.1038/onc.2011.572
- Araghi, M., Soerjomataram, I., Jenkins, M., Brierley, J., Morris, E., Bray, F., & Arnold, M. (2019). Global trends in colorectal cancer mortality: Projections to the year 2035. International Journal of Cancer, 144(12), 2992–3000. https://doi.org/https://doi.org/10.1002/ijc.32055
- Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020). A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chemistry, 103–811.
- Bracht, K., Nicholls, A. M., Liu, Y., & Bodmer, W. F. (2010). 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. British Journal of Cancer, 103(3), 340–346. https://doi.org/https://doi.org/10.1038/sj.bjc.6605780
- Brennan, P. J., Kumogai, T., Berezov, A., Murali, R., & Greene, M. I. (2000). HER2/neu: Mechanisms of dimerization/oligomerization. Oncogene, 19(53), 6093–6101. https://doi.org/https://doi.org/10.1038/sj.onc.1205119 https://doi.org/https://doi.org/10.1038/sj.onc.1203967
- Ellis, L. M., & Hicklin, D. J. (2008). VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nature Reviews. Cancer, 8(8), 579–591. https://doi.org/https://doi.org/10.1038/nrc2403
- Foley, J., Nickerson, N. K., Nam, S., Allen, K. T., Gilmore, J. L., Nephew, K. P., & Riese, D. J. II, (2010). EGFR signaling in breast cancer: Bad to the bone. Seminars in Cell & Developmental Biology, 21(9), 951–960. https://doi.org/https://doi.org/10.1016/j.semcdb.2010.08.009
- Forsythe, B., & Faulkner, K. (2004). Overview of the tolerability of Gefitinib (IRESSA) monotherapy: Clinical experience in non-small-cell lung cancer. Drug Safety, 27(14), 1081–1092. https://doi.org/https://doi.org/10.2165/00002018-200427140-00002
- Goel, G., & Sun, W. (2015). Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting-its impact on clinical practice. Journal of Hematology & Oncology, 8(1), 92. https://doi.org/https://doi.org/10.1186/s13045-015-0183-8
- Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, T., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology, 10(7), 1049–1056. https://doi.org/https://doi.org/10.1186/s13045-015-0183-8
- Ho, W. C., Dickson, K. M., & Barker, P. A. (2005). Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Research, 65(10), 4273–4281.https://doi.org/https://doi.org/10.1158/0008-5472
- Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular Biology International, 2014, 852748. https://doi.org/https://doi.org/10.1155/2014/852748
- Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52(7), 1757–1768. https://doi.org/https://doi.org/10.1021/ci3001277
- Jarvinen, T. A. H., Holli, K., Kuukasjarvi, T., & Isola, J. J. (1998). Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. British Journal of Cancer, 77(12), 2267–2273. https://doi.org/https://doi.org/10.1038/bjc.1998.377
- Johnston, S. R., & Leary, A. (2006). Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs of Today (Barcelona, Spain : 1998)), 42(7), 441–453. https://doi.org/https://doi.org/10.1358/dot.2006.42.7.985637
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J. (2007). Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine, 357(20), 2040–2048. https://doi.org/https://doi.org/10.1056/NEJMoa071834
- Karplus, M., & McCammon, J. A. (2002). Molecular dynamics simulations of biomolecules. Nature Structural Biology, 9(9), 646–652. https://doi.org/https://doi.org/10.1038/nsb0902-646
- Kingham, T. P., Alatise, O. I., Vanderpuye, V., Casper, C., Abantanga, F. A., Kamara, T. B., Olopade, O. I., Habeebu, M., Abdulkareem, F. B., & Denny, L. (2013). Treatment of cancer in sub-Saharan Africa. The Lancet. Oncology, 14(4), e158–167. https://doi.org/https://doi.org/10.1016/S1470-2045(12)70472-2
- Li, L., Wang, Y., Qi, B., Yuan, D., Dong, S., Guo, D., Zhang, C., & Yu, M. (2014). Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-κB-dependent MMP-9 expression. Oncology Reports, 32(5), 1779–1786. https://doi.org/https://doi.org/10.3892/or.2014.3422
- Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M., & MacKay, S. (2001). Nuclear factor-κB is upregulated in colorectal cancer. Surgery, 130(2), 363–369. https://doi.org/https://doi.org/10.1067/msy.2001.116672
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1–3), 3–25. https://doi.org/https://doi.org/10.1016/S0169-409X(96)00423-1
- Matikas, A., Georgoulias, V., & Kotsakis, A. (2016). The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: An update. Expert Review of Respiratory Medicine, 10(11), 1229–1241. https://doi.org/https://doi.org/10.1080/17476348.2016.1240620
- Messina, M. J., & Wood, C. E. (2008). Soy isoflavones, estrogen therapy, and breast cancer risk: Analysis and commentary. Nutrition Journal, 7(1), 17.https://doi.org/https://doi.org/10.1186/1475-2891-7-17
- O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3(1), 33. https://doi.org/https://doi.org/10.1186/1475-2891-7-17
- Ohashi, K., Sequist, L. V., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Moran, T., Camidge, D. R., Vnencak-Jones, C. L., Berry, L., Pan, Y., Sasaki, H., Engelman, J. A., Garon, E. B., Dubinett, S. M., Franklin, W. A., Riely, G. J., Sos, M. L., Kris, M. G., … Pao, W. (2013). Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research, 19(9), 2584–2591. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-12-3173
- Patel, A., & Sun, W. (2014). Ziv-aflibercept in metastatic colorectal cancer. Biologics: Targets & Therapy, 8, 13.
- Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., Strickland, A. H., Wilson, G., Ciuleanu, T.-E., Roman, L., Van Cutsem, E., Tzekova, V., Collins, S., Oliner, K. S., Rong, A., & Gansert, J. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(31), 4706–4713. https://doi.org/https://dx.doi.org/10.1200/JCO.2009.27.4860
- Peralta, E. A., Murphy, L. L., Minnis, J., Louis, S., & Dunnington, G. L. (2009). American Ginseng inhibits induced COX-2 and NFKB activation in breast cancer cells. Journal of Surgical Research, 157(2), 261–267. https://doi.org/https://doi.org/10.1016/j.jss.2009.05.011
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/https://doi.org/10.1002/jcc.20084
- Qawoogha, S. S., & Shahiwala, A. (2020). Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies. Journal of Receptor and Signal Transduction Research, 40(1), 67–76. https://doi.org/https://doi.org/10.1080/10799893.2020.1715431
- Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., Gonzalez-Larriba, J. L., Paz-Ares, L., Bover, I., Garcia-Campelo, R., Moreno, M. A., Catot, S., Rolfo, C., … Taron, M. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine, 361(10), 958–967. https://doi.org/https://doi.org/10.1056/NEJMoa0904554
- Sarfati, D., Koczwara, B., & Jackson, C. (2016). The impact of comorbidity on cancer and its treatment. CA: A Cancer Journal for Clinicians, 66(4), 337–350. https://doi.org/https://doi.org/10.3322/caac.21342
- Schwartz, P. A., & Murray, B. W. (2011). Protein kinase biochemistry and drug discovery. Bioorganic Chemistry, 39(5–6), 192–210. https://doi.org/https://doi.org/10.1016/j.bioorg.2011.07.004
- Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., Ponce, S., Lee, D. H., Liu, Y., Yoh, K., Zhou, J.-Y., Shi, X., Webster, A., Jiang, H., & Mok, T. S. K. (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. The Lancet Oncology, 16(8), 990–998. https://doi.org/https://doi.org/10.1016/S1470-2045(15)00121-7
- Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/https://doi.org/10.1002/jcc.21334
- Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615–2623. https://doi.org/https://doi.org/10.1021/jm020017n
- Wen, H., Jung, H., & Li, X. (2015). Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. The AAPS Journal, 17(6), 1327–1340.https://doi.org/https://doi.org/10.1021/jm020017n
- Wu, J. T., & Kral, J. G. (2005). The NF-κB/IκB signaling system: A molecular target in breast cancer therapy. Journal of Surgical Research, 123(1), 158–169. https://doi.org/https://doi.org/10.1016/j.jss.2004.06.006
- Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., Lu, S., Huang, Y., Geater, S. L., Lee, K. Y., Tsai, C.-M., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., … Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology, 16(2), 141–151. https://doi.org/https://doi.org/10.1016/S1470-2045(14)71173-8
- Yang, J. F., Wang, F., Chen, Y. Z., Hao, G. F., & Yang, G. F. (2019). LARMD: Integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor. Brief Bioinformatics, 1–13.
- Zubair, A., & Frieri, M. (2013). Role of nuclear factor-ĸB in breast and colorectal cancer. Current Allergy and Asthma Reports, 13(1), 44–49. https://doi.org/https://doi.org/10.1007/s11882-012-0300-5